This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bai, X.-F. Articles by Liu, Y. Search for Related Content PubMed PubMed Citation Articles by Bai, X.-F. Articles by Liu, Y.

Different Lineages of P1A-Expressing Cancer Cells Use Divergent Modes of Immune Evasion for T-Cell Adoptive Therapy

Department of Pathology and Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio

Requests for reprints: Xue-Feng Bai, Department of Pathology, Ohio State University Medical Center, 129 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210. Phone: 614-292-8649; Fax: 614-292-7072; E-mail: Xue-Feng.Bai{at}osumc.edu.

Tumor evasion of T-cell immunity remains a significant obstacle to adoptive T-cell therapy. It is unknown whether the mode of immune evasion is dictated by the cancer cells or by the tumor antigens. Taking advantage of the fact that multiple lineages of tumor cells share the tumor antigen P1A, we adoptively transferred transgenic T cells specific for P1A (P1CTL) into mice with established P1A-expressing tumors, including mastocytoma P815, plasmocytoma J558, and fibrosarcoma Meth A. Although P1CTL conferred partial protection, tumors recurred in almost all mice. Analysis of the status of the tumor antigen revealed that all J558 tumors underwent antigenic drift whereas all P815 tumors experienced antigenic loss. Interestingly, although Meth A cells are capable of both antigenic loss and antigenic drift, the majority of recurrent Meth A tumors retained P1A antigen. The ability of Meth A to induce apoptosis of P1CTL in vivo alleviated the need for antigenic drift and antigenic loss. Our data showed that, in spite of their shared tumor antigen, different lineages of cancer cells use different mechanisms to evade T-cell therapy. (Cancer Res 2006; 66(16):8241-9)

This article has been cited by other articles:

				A. Shanker, G. Verdeil, M. Buferne, E.-M. Inderberg-Suso, D. Puthier, F. Joly, C. Nguyen, L. Leserman, N. Auphan-Anezin, and A.-M. Schmitt-Verhulst CD8 T Cell Help for Innate Antitumor Immunity J. Immunol., November 15, 2007; 179(10): 6651 - 6662. [Abstract] [Full Text] [PDF]